| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4086 | 2018 |
| Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial P Sharma, M Retz, A Siefker-Radtke, A Baron, A Necchi, J Bedke, ... The lancet oncology 18 (3), 312-322, 2017 | 1743 | 2017 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 725 | 2019 |
| Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study MO Grimm, C Steinhoff, X Simon, P Spiegelhalder, R Ackermann, ... The Journal of urology 170 (2), 433-437, 2003 | 472 | 2003 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, ... ESMO open 5 (6), e001079, 2020 | 471 | 2020 |
| Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, ... Annals of Oncology 31 (8), 1030-1039, 2020 | 401 | 2020 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 399 | 2020 |
| Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study D Jocham, F Witjes, S Wagner, B Zeylemaker, J van MOORSELAAR, ... The Journal of urology 174 (3), 862-866, 2005 | 368 | 2005 |
| The contemporary concept of significant versus insignificant prostate cancer G Ploussard, JI Epstein, R Montironi, PR Carroll, M Wirth, MO Grimm, ... European urology 60 (2), 291-303, 2011 | 364 | 2011 |
| Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions JC Hassel, L Heinzerling, J Aberle, O Bähr, TK Eigentler, MO Grimm, ... Cancer treatment reviews 57, 36-49, 2017 | 318 | 2017 |
| A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of … JA Thomas, A Tubaro, N Barber, F d’Ancona, G Muir, U Witzsch, ... European urology 69 (1), 94-102, 2016 | 298 | 2016 |
| A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma C Wülfing, JPH Machiels, DJ Richel, MO Grimm, U Treiber, MR De Groot, ... Cancer 115 (13), 2881-2890, 2009 | 265 | 2009 |
| Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial D Cella, V Grünwald, B Escudier, HJ Hammers, S George, P Nathan, ... The Lancet Oncology 20 (2), 297-310, 2019 | 254 | 2019 |
| 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of … A Bachmann, A Tubaro, N Barber, F d’Ancona, G Muir, U Witzsch, ... European urology 65 (5), 931-942, 2014 | 249 | 2014 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 243 | 2017 |
| Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a … RJ Motzer, B Escudier, DF McDermott, OA Frontera, B Melichar, T Powles, ... Journal for immunotherapy of cancer 8 (2), 2020 | 202 | 2020 |
| Assessment of PI-RADS v2 for the detection of prostate cancer M Kasel-Seibert, T Lehmann, R Aschenbach, FV Guettler, M Abubrig, ... European journal of radiology 85 (4), 726-731, 2016 | 193 | 2016 |
| An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer SV Lindskrog, F Prip, P Lamy, A Taber, CS Groeneveld, ... Nature communications 12 (1), 2301, 2021 | 189 | 2021 |
| Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma RJ Motzer, DF McDermott, B Escudier, M Burotto, TK Choueiri, ... Cancer 128 (11), 2085-2097, 2022 | 179 | 2022 |
| A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign … A Bachmann, A Tubaro, N Barber, F d’Ancona, G Muir, U Witzsch, ... The Journal of urology 193 (2), 570-578, 2015 | 170 | 2015 |
